Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emdogain FL in Stage III Periodontitis
NCT05418621Phase 3Unknown
- Sponsor
- University of Pisa
- Start
- Mar 2021
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enamel matrix derivative in periodontitis (2 arms), sponsored by University of Pisa. Primary endpoint: Resolved cases at 12 months. Status: unknown.
02
Drugs
enamel matrix derivative
03
Conditions
periodontitis
Beyond the preview
Go deeper on NCT05418621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418621.